Volume 66, Issue 1, Pages (July 2004)

Slides:

Advertisements

Similar presentations

Ischemic heart disease after renal transplantation

Advertisements

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Volume 54, Issue 4, Pages (October 1998)

KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient Christoph Wanner,

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Volume 79, Issue 9, Pages (May 2011)

Bettina Haslinger-Löffler Kidney International

Lipopheresis in the nephrotic syndrome

Volume 55, Issue 2, Pages (February 1999)

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Section 5: Dialysis Interventions for Treatment of AKI

Volume 26, Issue 2, Pages (February 2018)

Volume 58, Issue 1, Pages (July 2000)

Peripheral microvascular parameters in the nephrotic syndrome

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Abnormalities in lipoprotein metabolism in hemodialysis patients

The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease Harm H.H. Feringa, MD, Stefanos.

Methotrexate in the urine

Per-Ola Attman, M.D, Petar Alaupovic, Ola Samuelsson

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

Volume 56, Pages S122-S125 (July 1999)

Volume 55, Issue 3, Pages (March 1999)

Volume 56, Issue 3, Pages (September 1999)

Volume 87, Issue 2, Pages (February 2015)

New insights into lipid metabolism in the nephrotic syndrome

Volume 70, Issue 12, Pages (December 2006)

Infected glomerulus Kidney International

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

Volume 87, Issue 1, Pages (January 2015)

A physician's perseverance uncovers problems in a key nephrology study

Reduced bone mineral density in adults treated with high-dose corticosteroids for childhood nephrotic syndrome Janet Hegarty, M. Zulf Mughal, Judith.

Günter Weiss, Florian Kronenberg Kidney International

Extracorporeal therapy in sepsis: are we there yet?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Rhanderson Cardoso, MD, Roger S

Volume 87, Issue 1, Pages (January 2015)

Volume 67, Issue 4, Pages (April 2005)

Simvastatin in nephrotic syndrome

Volume 66, Issue 3, Pages (September 2004)

Nephrology Crossword: Glomerulonephritis

In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)

V.R. Sørensen, P.M. Hansen, J. Heaf, B. Feldt-Rasmussen

Volume 56, Pages S235-S237 (July 1999)

Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients Florian Kronenberg, Arno Lingenhel, Ulrich Neyer, Karl Lhotta, Paul König, Martin.

Volume 71, Issue 4, Pages (February 2007)

Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis N.-Y. Zalunardo, C.-L. Rose, I.W.Y.

Volume 54, Issue 4, Pages (October 1998)

Mediterranean diets: are they practical in the Western world?

Organ transplantation goes to the movies

Atherosclerotic nephropathy

Volume 65, Issue 2, Pages (February 2004)

Volume 56, Pages S28-S30 (July 1999)

Effect of lipid-lowering strategies on tubular cell biology

Volume 75, Issue 4, Pages (February 2009)

Is complement a target for therapy in renal disease?

Yutaka Koda, M.D., Shin-Ichi Nishi, Masashi Suzuki, Yoshihei Hirasawa

Volume 70, Issue 5, Pages (September 2006)

The changing face of childhood nephrotic syndrome

Dana V. Rizk, David G. Warnock Kidney International

Ischemic heart disease after renal transplantation

The International Pediatric Peritonitis Registry: Starting to walk

Familial phenotype differences in PKD11

Volume 57, Issue 2, Pages (October 2000)

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

Lipoprotein abnormalities in diabetic nephropathy

Prediction in idiopathic membranous nephropathy

Volume 62, Issue 2, Pages (August 2002)

The cost of starting and maintaining a large home hemodialysis program

Peter Stenvinkel, Olof Heimbürger, Catherine H. Tuck, Lars Berglund

Presentation transcript:

Volume 66, Issue 1, Pages 348-354 (July 2004) Lipoprotein(a)- and low-density lipoprotein–derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? Florian Kronenberg, Arno Lingenhel, Karl Lhotta, Barbara Rantner, Martina F. Kronenberg, Paul König, Joachim Thiery, Michael Koch, Arnold Von Eckardstein, Hans Dieplinger Kidney International Volume 66, Issue 1, Pages 348-354 (July 2004) DOI: 10.1111/j.1523-1755.2004.00737.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Lipoprotein(a) [Lp(a)]-derived low-density lipoprotein (LDL) cholesterol in controls and patients with nephrotic syndrome stratified by six apolipoprotein(a) [apo(a)] phenotype groups. Patients with nephrotic syndrome had three times the amount of Lp(a)-derived LDL cholesterol compared to controls (overall 27 mg/dL vs. 9 mg/dL). Patients with low-molecular-weight (LMW) compared to patients with high-molecular weight (HMW) apo(a) phenotypes showed a significantly higher amount of Lp(a)-derived LDL cholesterol (47.8 ± 51.8 mg/dL vs. 15.7 ± 21.1 mg/dL, P < 0.001). K-IV is kringle IV. Kidney International 2004 66, 348-354DOI: (10.1111/j.1523-1755.2004.00737.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Low-density lipoprotein (LDL) cholesterol and lipoprotein(a) [Lp(a)]-corrected LDL cholesterol levels in patients with low-molecular-weight (LMW) and high-molecular-weight (HMW) apolipoprotein(a) [apo(a)] phenotypes. Only patients are presented who showed at least 30 mg/dL difference between the two LDL cholesterol levels. This was significantly less the case in patients with HMW than in those with LMW apo(a) phenotypes (16% vs. 58%; P < 0.00001). Kidney International 2004 66, 348-354DOI: (10.1111/j.1523-1755.2004.00737.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 3 Low density lipoprotein (LDL) cholesterol and lipoprotein(a) [Lp(a)]-corrected LDL cholesterol levels in patients who showed an LDL cholesterol level ≥100 mg/dL which was below 100 mg/dL after correction for Lp(a)-derived LDL cholesterol. The analysis is stratified for low-molecular-weight (LMW) and high-molecular weight (HMW) apolipoprotein(a) [apo(a)] phenotypes and shows tremendous differences between the two phenotype groups (25.7% vs. 2.3%, P < 0.00001). Kidney International 2004 66, 348-354DOI: (10.1111/j.1523-1755.2004.00737.x) Copyright © 2004 International Society of Nephrology Terms and Conditions